Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
PubMed
Google Scholar
Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30.
Article
PubMed
Google Scholar
Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
Article
PubMed
Google Scholar
Luo Q, Cui M, Deng Q, et al. Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma. Mol Med Rep. 2019;19(6):4685–96.
CAS
PubMed
PubMed Central
Google Scholar
Durinck S, Stawiski EW, Pavía-Jiménez A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genetics. 2015;47(1):13–21.
Article
CAS
PubMed
Google Scholar
Courthod G, Tucci M, Di Maio M, et al. Papillary renal cell carcinoma: a review of the current therapeutic landscape. Crit Rev Oncol Hematol. 2015;96(1):100–12.
Article
PubMed
Google Scholar
Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22–36.
Article
CAS
PubMed
Google Scholar
Laduca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2000 patients. Genet Med. 2014;16(11):830–7.
Article
PubMed
PubMed Central
Google Scholar
Ye M, He Z, Dai W, et al. TOP2AA -derived cancer panel drives cancer progression in papillary renal cell carcinoma. Oncol Lett. 2018;16(4):4169–78.
PubMed
PubMed Central
Google Scholar
Mckay RR, Bossé D, Xie W, et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res. 2018;6(7):758–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.
Article
CAS
PubMed
Google Scholar
Wang Z, Song Q, Yang Z, et al. Construction of immune-related risk signature for renal papillary cell carcinoma. Cancer Med. 2019;8(1):289–304.
Article
CAS
PubMed
Google Scholar
Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11(16):5730–9.
Article
CAS
PubMed
Google Scholar
Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yusenko MV, Kuiper RP, Boethe T, et al. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer. 2009;9:152.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liao Y, Wang J, Jaehnig EJ, et al. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199–205.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
Article
CAS
PubMed
PubMed Central
Google Scholar
Da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.
Article
CAS
Google Scholar
Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–2.
Article
CAS
PubMed
Google Scholar
Yang H, Wu J, Zhang J, et al. Integrated bioinformatics analysis of key genes involved in progress of colon cancer. Mol Genet Genomic Med. 2019;7(4):e00588.
Article
PubMed
PubMed Central
CAS
Google Scholar
Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.
Article
CAS
PubMed
Google Scholar
Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;2014:S11.
Article
Google Scholar
Ricketts CJ, De Cubas AA, Fan H, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313-326.e315.
Article
CAS
PubMed
PubMed Central
Google Scholar
Scott AC, Dündar F, Zumbo P, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270–4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Khan O, Giles JR, Mcdonald S, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Alfei F, Kanev K, Hofmann M, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571(7764):265–9.
Article
CAS
PubMed
Google Scholar
Massari F, Di Nunno V, Guida A, et al. Addition of primary metastatic site on bone, brain, and liver to IMDC criteria in patients with metastatic renal cell carcinoma: a validation study. Clin Genitourin Cancer. 2021;19(1):32–40.
Article
PubMed
Google Scholar
Akhtar M, Al-Bozom IA, Al Hussain HT. Papillary renal cell carcinoma (PRCC): an update. Adv Anat Pathol. 2019;26(2):124–32.
Article
PubMed
Google Scholar
Massari F, Di Nunno V, Santoni M, et al. Toward a genome-based treatment landscape for renal cell carcinoma. Crit Rev Oncol Hematol. 2019;142:141–52.
Article
PubMed
Google Scholar
Robertson-Tessi M, Gillies RJ, Gatenby RA, et al. Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. 2015;75(8):1567–79.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest. 2013;123(9):3652–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45.
Article
PubMed
CAS
Google Scholar
Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–52.
Article
CAS
PubMed
Google Scholar
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma Q, Xu Y, Liao H, et al. Identification and validation of key genes associated with non-small-cell lung cancer. J Cell Physiol. 2019;234(12):22742–52.
Article
CAS
PubMed
Google Scholar
Harjunpää H, Llort Asens M, Guenther C, et al. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078.
Article
PubMed
PubMed Central
CAS
Google Scholar
Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127(3):780–9.
Article
PubMed
PubMed Central
Google Scholar
Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature. 2005;437(7058):505–11.
Article
CAS
PubMed
Google Scholar
Yuan K, Ye J, Liu Z, et al. Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. J Exp Clin Cancer Res. 2020;39(1):9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim PY, Tan O, Diakiw SM, et al. Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. J Proteomics. 2014;96:1–12.
Article
CAS
PubMed
Google Scholar
Markiewski MM, Deangelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9(11):1225–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rutkowski MJ, Sughrue ME, Kane AJ, et al. Cancer and the complement cascade. Mol Cancer Res. 2010;8(11):1453–65.
Article
CAS
PubMed
Google Scholar
Pang JS, Li ZK, Lin P, et al. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: a study based on TCGA and Cmap datasets. Oncol Rep. 2019;41(4):2089–102.
CAS
PubMed
PubMed Central
Google Scholar
Kitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 2005;65(5):1719–28.
Article
CAS
PubMed
Google Scholar
Körner M, Waser B, Reubi JC. High expression of neuropeptide Y1 receptors in ewing sarcoma tumors. Clin Cancer Res. 2008;14(16):5043–9.
Article
PubMed
Google Scholar
Ruscica M, Dozio E, Boghossian S, et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology. 2006;147(3):1466–73.
Article
CAS
PubMed
Google Scholar
Lv X, Zhao F, Huo X, et al. Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma. Med Oncol. 2016;33(7):70.
Article
PubMed
CAS
Google Scholar
Ishihara K, Kamata M, Hayashi I, et al. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol. 2002;2(4):499–509.
Article
CAS
PubMed
Google Scholar
Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer. 2002;98(1):29–35.
Article
CAS
PubMed
Google Scholar
Bettigole SE, Glimcher LH. Endoplasmic reticulum stress in immunity. Annu Rev Immunol. 2015;33:107–38.
Article
CAS
PubMed
Google Scholar
Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol. 2008;8(9):663–74.
Article
CAS
PubMed
Google Scholar
Rausch MP, Sertil AR. A stressful microenvironment: opposing effects of the endoplasmic reticulum stress response in the suppression and enhancement of adaptive tumor immunity. Int Rev Immunol. 2015;34(2):104–22.
Article
CAS
PubMed
Google Scholar
Kobayashi M, Nagashio R, Jiang SX, et al. Calnexin is a novel sero-diagnostic marker for lung cancer. Lung Cancer. 2015;90(2):342–5.
Article
PubMed
Google Scholar
Turano C, Gaucci E, Grillo C, et al. ERp57/GRP58: a protein with multiple functions. Cell Mol Biol Lett. 2011;16(4):539–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hettinghouse A, Liu R, Liu CJ. Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol Ther. 2018;181:34–48.
Article
CAS
PubMed
Google Scholar
Choe MH, Min JW, Jeon HB, et al. ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer. Oncotarget. 2015;6(5):2654–66.
Article
PubMed
PubMed Central
Google Scholar
Shimoda T, Wada R, Kure S, et al. Expression of protein disulfide isomerase A3 and its clinicopathological association in gastric cancer. Oncol Rep. 2019;41(4):2265–72.
CAS
PubMed
Google Scholar
Takata H, Kudo M, Yamamoto T, et al. Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma. Oncol Lett. 2016;12(6):4896–904.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zou H, Wen C, Peng Z, et al. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas. Oncol Rep. 2018;39(2):501–10.
CAS
PubMed
Google Scholar
Liu X, Song N, Liu Y, et al. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens. Cell Immunol. 2015;295(2):77–82.
Article
CAS
PubMed
Google Scholar
Siebenkäs C, Chiappinelli KB, Guzzetta AA, et al. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS ONE. 2017;12(6):e0179501.
Article
PubMed
PubMed Central
CAS
Google Scholar
Langer R, Feith M, Siewert JR, et al. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008;8:70.
Article
PubMed
PubMed Central
CAS
Google Scholar
Takahashi H, Wang JP, Zheng HC, et al. Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis. Histol Histopathol. 2011;26(6):663–71.
PubMed
Google Scholar
Yang Z, Zhuang L, Szatmary P, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015;12(3):256–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zheng HC, Takahashi H, Li XH, et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol. 2008;39(7):1042–9.
Article
CAS
PubMed
Google Scholar
Negroni L, Taouji S, Arma D, et al. Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers. Mol Cell Proteomics. 2014;13(12):3473–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shen H, Huang J, Pei H, et al. Comparative proteomic study for profiling differentially expressed proteins between Chinese left- and right-sided colon cancers. Cancer Sci. 2013;104(1):135–41.
Article
CAS
PubMed
Google Scholar
Xia W, Zhuang J, Wang G, et al. P4HB promotes HCC tumorigenesis through downregulation of GRP78 and subsequent upregulation of epithelial-to-mesenchymal transition. Oncotarget. 2017;8(5):8512–21.
Article
PubMed
Google Scholar
Zhang J, Wu Y, Lin YH, et al. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer. World J Gastroenterol. 2018;24(22):2381–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Althurwi SI, Yu JQ, Beale P, et al. Sequenced combinations of cisplatin and selected phytochemicals towards overcoming drug resistance in ovarian tumour models. Int J Mol Sci. 2020;21:20.
Article
CAS
Google Scholar
Sun S, Lee D, Ho AS, et al. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol. 2013;15(5):562–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu Z, He A, Lv T, et al. Overexpression of P4HB is correlated with poor prognosis in human clear cell renal cell carcinoma. Cancer Biomark Sect A Dis Mark. 2019;26(4):431–9.
Article
CAS
Google Scholar
Nunno VD, Mollica V, Gatto L, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. 2019;11(7):631–43.
Article
CAS
PubMed
Google Scholar
Schaefer K, Webb NE, Pang M, et al. Galectin-9 binds to O-glycans on protein disulfide isomerase. Glycobiology. 2017;27(9):878–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bortnov V, Annis DS, Fogerty FJ, et al. Myeloid-derived growth factor is a resident endoplasmic reticulum protein. J Biol Chem. 2018;293(34):13166–75.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hurst KE, Lawrence KA, Reyes Angeles L, et al. Endoplasmic reticulum protein disulfide isomerase shapes T cell efficacy for adoptive cellular therapy of tumors. Cells. 2019;8(12):1514.
Article
CAS
PubMed Central
Google Scholar
Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125(9):3347–55.
Article
PubMed
PubMed Central
Google Scholar
Mollica V, Di Nunno V, Gatto L, et al. Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. Cancers (Basel). 2019;11(6):830.
Article
Google Scholar
Ciccarese C, Di Nunno V, Iacovelli R, et al. Future perspectives for personalized immunotherapy in renal cell carcinoma. Expert Opin Biol Ther. 2017;17(9):1049–52.
Article
CAS
PubMed
Google Scholar
Shin SJ, Jeon YK, Kim PJ, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol. 2016;23(2):694–702.
Article
PubMed
Google Scholar
Okadome K, Baba Y, Nomoto D, et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. Br J Cancer. 2020;122(10):1535–43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mollica V, Di Nunno V, Gatto L, et al. Novel therapeutic approaches and targets currently under evaluation for renal cell carcinoma: waiting for the revolution. Clin Drug Investig. 2019;39(6):503–19.
Article
PubMed
Google Scholar
Santoni M, Massari F, Piva F, et al. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018;19(9):1021–5.
Article
CAS
PubMed
Google Scholar
Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Khan O, Giles JR, Mcdonald S, et al. TOX transcriptionally and epigenetically programs CD8 T cell exhaustion. Nature. 2019;571(7764):211–8.
Article
CAS
PubMed
PubMed Central
Google Scholar